GLP-1
-
healthSemaglutide Shows Promise in Reversing Osteoarthritis Damage
New research suggests semaglutide, known for diabetes and weight loss, may reverse joint tissue damage in osteoarthritis by reprogramming cell metabolism.
-
healthNew Pill Orforglipron Outperforms Ozempic in Key Diabetes and Weight Loss Trial
A groundbreaking Phase 3 trial reveals orforglipron, an oral GLP-1 drug, demonstrates superior efficacy in blood sugar control and weight reduction compared to oral semaglutide.
-
healthUnregulated Peptide 'Grey Market' Fuels Self-Injection Trend
Millions are injecting peptides sold 'for research purposes only,' bypassing safety regulations and risking serious health consequences.
-
healthWeight-Loss Drugs: Unexpected Impacts on Sexual Health Explored
New research reveals GLP-1 weight-loss medications have varied effects on sexual health, influencing libido, function, and body image in both men and women.
-
healthBeware of Compounded GLP-1 Drugs: Risks and Realities
Understand the critical differences between FDA-approved and compounded GLP-1 medications. Protect your health from unregulated and potentially dangerous alternatives.
-
healthNovo Nordisk Slashes Ozempic & Wegovy Prices Amid Fierce Competition
Novo Nordisk announces significant list price reductions for Ozempic and Wegovy, aiming to boost affordability for insured patients amidst rising competition and market pressures.